Description: HBM Holdings Limited, a clinical-stage biopharmaceutical company, engages in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. It is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor; Tanfanercept (HBM9036) to treat moderate to-severe dry eye disease; HBM7008, a bispecific antibody targeting tumor Associated antigen; and HBM4003, a human anti-CTLA-4 antibody against cytotoxic T-lymphocyte-associated antigen-4. The company is also developing HBM9022 for the treatment of SARS-COV-2; HBM9302 for the treatment of breast and gastric cancers; HBM7020 for the treatment of multiple myeloma; and HBM1007, HBM1029, HBM7015, HBM7008, and HBM1022 for the treatment of solid tumors. It operates in Mainland China, the United States, Europe, and internationally. The company has collaboration on antibody-drug conjugate projects with LegoChem Biosciences Inc. and Duality Biotherapeutics, Inc. HBM Holdings Limited was incorporated in 2016 and is based in Shanghai, the People's Republic of China.
Home Page: www.harbourbiomed.com
Tower A, 12th Floor
Shanghai,
200032
China
Phone:
86 21 5339 9123
Officers
| Name | Title |
|---|---|
| Dr. Jingsong Wang M.D., Ph.D. | Founder, Chairman & CEO |
| Mr. Weihao Xu | CFO, Chief Bus. Officer and Global Head of Bus. & Corp. Devel. |
| Dr. Frank Grosveld | Founding Chief Scientific Officer & Member of Scientific Advisory Board |
| Mr. Bruce Zhang | Head of Legal |
| Dr. Peter F. Moesta Ph.D. | Member of Scientific Advisory Board & Chief CMC Advisor |
| Dr. George Liu | Head of Early Devel. and Scientific Operations |
| Mr. Liu Lile | Sr. VP, Head of Technology Platform & Head of Suzhou Operations |
| Dr. Yiping Rong Ph.D. | Sr. VP, Head of Discovery & Exec. Director |
| Dr. Humphrey A. R. Gardner FCAP, M.D. | Chief Medical Officer |
| Dr. Xiaolu Tao | Sr. VP & Head of Translational Devel. |
Exchange: HK
Country: HK
Currency: Hong Kong Dollar (HK$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.0818 |
| Price-to-Sales TTM: | 49.6607 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 396 |